Queries on Rilonacept in COVID-19 and Vaccine-Linked Pericarditis: Addressing Study Outcomes.
作者信息
Albulushi Arif, Al-Jabri Adil, Al-Amri Amir
机构信息
Department of Adult Cardiology, National Heart Center, The Royal Hospital, Muscat, Oman.
出版信息
CJC Open. 2024 May 1;6(8):1032. doi: 10.1016/j.cjco.2024.04.009. eCollection 2024 Aug.
Abstract
摘要
相似文献
1
Queries on Rilonacept in COVID-19 and Vaccine-Linked Pericarditis: Addressing Study Outcomes.关于利罗那肽在新冠病毒疾病和疫苗相关心包炎中的疑问：探讨研究结果
CJC Open. 2024 May 1;6(8):1032. doi: 10.1016/j.cjco.2024.04.009. eCollection 2024 Aug.
2
Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term Extension.接受利罗那肽治疗的 COVID-19 患者和接种 SARS-CoV-2 疫苗后心包炎未复发：RHAPSODY 长期扩展研究结果
CJC Open. 2024 Mar 4;6(6):805-810. doi: 10.1016/j.cjco.2024.02.002. eCollection 2024 Jun.
3
Rilonacept and Anakinra in Recurrent Pericarditis: A Systematic Review and Meta-Analysis.利罗那肽和阿那白滞素治疗复发性心包炎的系统评价与荟萃分析
Cureus. 2022 Nov 8;14(11):e31226. doi: 10.7759/cureus.31226. eCollection 2022 Nov.
4
Sustained Pericarditis Recurrence Risk Reduction With Long-Term Rilonacept.长期用利纳西普降低持续性心包炎复发风险。
J Am Heart Assoc. 2024 Mar 19;13(6):e032516. doi: 10.1161/JAHA.123.032516. Epub 2024 Mar 12.
5
Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial.利罗西普治疗复发性心包炎的疗效和安全性：一项II期临床试验的结果
Heart. 2020 Nov 23;107(6):488-96. doi: 10.1136/heartjnl-2020-317928.
6
Interleukin-1 Trap Rilonacept Improved Health-Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY.白细胞介素-1 陷阱利纳西普在复发性心包炎患者中改善健康相关生活质量和睡眠：来自 3 期临床试验 RHAPSODY 的结果。
J Am Heart Assoc. 2022 Oct 18;11(20):e023252. doi: 10.1161/JAHA.121.023252. Epub 2022 Oct 17.
7
Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis.从口服药物转换为利那洛肽单药治疗复发性心包炎患者。
Heart. 2023 Jan 27;109(4):297-304. doi: 10.1136/heartjnl-2022-321328.
8
Rilonacept use in lupus pericarditis.利那洛肽治疗狼疮性心包炎。
Clin Exp Rheumatol. 2024 May;42(5):1115-1117. doi: 10.55563/clinexprheumatol/pb3hzb. Epub 2024 Mar 19.
9
Rilonacept: A Newly Approved Treatment for Recurrent Pericarditis.利那洛肽：一种新批准的复发性心包炎治疗方法。
Ann Pharmacother. 2022 May;56(5):572-581. doi: 10.1177/10600280211036499. Epub 2021 Aug 28.
10
Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis.白细胞介素-1受体拮抗剂rilonacept治疗复发性心包炎的3期试验
N Engl J Med. 2021 Jan 7;384(1):31-41. doi: 10.1056/NEJMoa2027892. Epub 2020 Nov 16.
本文引用的文献
1
Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term Extension.接受利罗那肽治疗的 COVID-19 患者和接种 SARS-CoV-2 疫苗后心包炎未复发：RHAPSODY 长期扩展研究结果
CJC Open. 2024 Mar 4;6(6):805-810. doi: 10.1016/j.cjco.2024.02.002. eCollection 2024 Jun.
2
Anti-inflammatory therapies for pericardial diseases in the COVID-19 pandemic: safety and potentiality.COVID-19 大流行期间心包疾病的抗炎治疗：安全性和潜力。
J Cardiovasc Med (Hagerstown). 2020 Sep;21(9):625-629. doi: 10.2459/JCM.0000000000001059.
3
Complicated Pericarditis: Understanding Risk Factors and Pathophysiology to Inform Imaging and Treatment.复杂性心包炎：了解风险因素和病理生理学，以指导影像学和治疗。
J Am Coll Cardiol. 2016 Nov 29;68(21):2311-2328. doi: 10.1016/j.jacc.2016.07.785.
Zotero 插件